文章：

INPP5F基因表达作为氟达拉滨为基础治疗慢性淋巴细胞白血病中的独立预后标志物

Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia

原文发布日期：2015-10-02

DOI: 10.1038/bcj.2015.82

类型: Original Article

开放获取: 是

英文摘要：

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease. Various disease-related and patient-related factors have been shown to influence the course of the disease. The aim of this study was to identify novel biomarkers of significant clinical relevance. Pretreatment CD19-separated lymphocytes (n=237; discovery set) and peripheral blood mononuclear cells (n=92; validation set) from the REACH trial, a randomized phase III trial in relapsed CLL comparing rituximab plus fludarabine plus cyclophosphamide with fludarabine plus cyclophosphamide alone, underwent gene expression profiling. By using Cox regression survival analysis on the discovery set, we identified inositol polyphosphate-5-phosphatase F (INPP5F) as a prognostic factor for progression-free survival (P<0.001; hazard ratio (HR), 1.63; 95% confidence interval (CI), 1.35–1.98) and overall survival (P<0.001; HR, 1.47; 95% CI, 1.18–1.84), regardless of adjusting for known prognostic factors. These findings were confirmed on the validation set, suggesting that INPP5F may serve as a novel, easy-to-assess future prognostic biomarker for fludarabine-based therapy in CLL.

摘要翻译： 

慢性淋巴细胞白血病（CLL）是一种异质性疾病。研究表明，多种疾病相关因素和患者自身因素均可影响疾病进程。本研究旨在发现具有显著临床意义的新型生物标志物。我们采用REACH试验（一项针对复发CLL的随机III期临床试验，比较利妥昔单抗联合氟达拉滨/环磷酰胺与单用氟达拉滨/环磷酰胺的疗效）中获取的CD19分选淋巴细胞（n=237；发现集）和外周血单个核细胞（n=92；验证集）进行基因表达谱分析。通过对发现集进行Cox回归生存分析，我们发现多磷酸肌醇-5-磷酸酶F（INPP5F）是无进展生存期（P<0.001；风险比1.63；95%置信区间1.35-1.98）和总生存期（P<0.001；风险比1.47；95%置信区间1.18-1.84）的预后影响因素，且该关联在调整已知预后因素后依然存在。这些发现在验证集中得到证实，提示INPP5F有望成为评估CLL患者氟达拉滨基础治疗方案的新型、易检测的预后生物标志物。

原文链接：

Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia